Provided by Tiger Fintech (Singapore) Pte. Ltd.

CureVac B.V.

5.39
-0.0100-0.19%
Volume:339.63K
Turnover:1.83M
Market Cap:1.21B
PE:5.36
High:5.40
Open:5.38
Low:5.37
Close:5.40
52wk High:5.72
52wk Low:2.37
Shares:225.17M
Float Shares:125.87M
Volume Ratio:0.89
T/O Rate:0.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.01
EPS(LYR):0.7483
ROE:40.22%
ROA:23.77%
PB:1.78
PE(LYR):7.20

Loading ...

CureVac Q1 Sales $946.45K Miss $3.34M Estimate, Company Exits Quarter With Cash And Equivalents Worth $460.91M

Benzinga
·
May 20

BRIEF-Curevac Q1 Revenue Eur 900 Thousand

Reuters
·
May 20

CureVac NV expected to post a loss of 19 cents a share - Earnings Preview

Reuters
·
May 19

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 19

CureVac (CVAC) Receives a Hold from Leerink Partners

TIPRANKS
·
May 19

BRIEF-Curevac Receives Additional Positive Validity Decision From European Patent Office In Ongoing Litigation Against Biontech SE

Reuters
·
May 16

Curevac Is Maintained at Buy by UBS

Dow Jones
·
Apr 30

UBS Trims Price Target on CureVac to $12 From $13, Maintains Buy Rating

MT Newswires Live
·
Apr 30

CureVac Among 3 Promising Penny Stocks To Watch

Simply Wall St.
·
Apr 14

Stock Track | CureVac Shares Soar 5% in Pre-market on Strong 2024 Financial Results and Pipeline Progress

Stock Track
·
Apr 11

CureVac NV (CVAC) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Financial Resilience

GuruFocus.com
·
Apr 11

Q4 2024 CureVac NV Earnings Call

Thomson Reuters StreetEvents
·
Apr 11

CureVac Stock (CVAC) Dips Despite Promising Treatment Pipeline

TIPRANKS
·
Apr 11

Stock Track | CureVac Shares Plummet 5% Pre-Market on Wider Q4 Losses and Revenue Decline

Stock Track
·
Apr 11

Stock Track | CureVac Shares Plummet 5.03% After Q4 Loss and Mixed 2024 Results

Stock Track
·
Apr 11

CureVac's Cash And Cash Equivalents Position Of €481.7M As Of December 31, 2024; Reaffirming Expected Cash Runway Into 2028

Benzinga
·
Apr 10

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

ACCESS Newswire
·
Apr 10

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Apr 10

CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025

ACCESS Newswire
·
Apr 08

CureVac Receives FDA Clearance to Initiate Phase 1 Trial of Lung Cancer Therapy

MT Newswires Live
·
Apr 07